No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.
What new management means for Mylan shareholders moving forward.
Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.
Is a turnaround even possible anymore?
Will BBBY be the next retailer to bite the dust?
There are no signs of accumulation of the beleaguered bank's shares and a sustainable base pattern is lacking.
Deutsche is looking to drop the "bad bank" moniker with big moves on Monday.
The $17 billion acquisition of Caesars by Eldorado is welcomed by activist investor Carl Icahn, who had been pushing Caesars board for a deal.
Is breaking up big tech just another big headache?
But is a Teva turnaround still coming after the stock's 70% loss in the past five years?